{"id":11838,"date":"2021-03-02T15:33:52","date_gmt":"2021-03-02T10:03:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11838"},"modified":"2025-02-12T17:41:18","modified_gmt":"2025-02-12T12:11:18","slug":"pharma-happenings-for-az-evotec-chinook-junshi-hitgen","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen","title":{"rendered":"Evotec, Chinook Teams Up for CKD Therapy; HitGen &#038; UPPTHERA in Drug Delivery Research; Artiva&#8217;s $120 M Coup of NK Cell Therapy; Junshi &#038; AZ with Toripalimab in China"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a091bdb88ee0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a091bdb88ee0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen\/#Evotec_Chinook_Therapeutics_to_Advance_Chronic_Kidney_Diseases_Therapy_Market\" >Evotec, Chinook Therapeutics to Advance Chronic Kidney Diseases Therapy Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen\/#HitGen_UPPTHERA_Collaborate_for_Drug_Delivery_Research\" >HitGen &amp; UPPTHERA Collaborate for Drug Delivery Research&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen\/#Junshi_AstraZeneca_To_Commercialize_Toripalimab_in_China\" >Junshi &amp; AstraZeneca To Commercialize Toripalimab in China<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen\/#Artiva_Raises_USD_120_M_to_Advancing_Allogeneic_NK_Cell_Therapy_Pipeline\" >Artiva Raises USD 120 M to Advancing Allogeneic NK Cell Therapy Pipeline<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-evotec-chinook-therapeutics-to-advance-chronic-kidney-diseases-therapy-market\"><span class=\"ez-toc-section\" id=\"Evotec_Chinook_Therapeutics_to_Advance_Chronic_Kidney_Diseases_Therapy_Market\"><\/span><strong>Evotec, Chinook Therapeutics to Advance Chronic Kidney Diseases Therapy Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine therapies for patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-chronic-renal-failure-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">chronic kidney diseases<\/a> (CKD). The duo plans to jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines.<\/p>\n\n\n\n<p>The deal will help leverage Evotec&#8217;s proprietary <strong>PanOmics <\/strong>platform that incorporates enhanced throughput proteomics, high throughput transcriptomics, and cell imaging with <strong>PanHunter<\/strong>, which is Evotec&#8217;s unique integrated data analysis platform. Chinook will have access to the NURTuRE cohort study along with other proprietary patient biobanks and Evotec&#8217;s multi-omics integration platform, and the company plans to potentially deliver targeted therapies in rare kidney diseases such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">IgA nephropathy<\/a> and glomerular diseases.<\/p>\n\n\n\n<p>To sum it, Chinook will manage clinical development and commercialization of product candidates while Evotec will be eligible for an undisclosed upfront payment, research funding, progress-dependent milestone payments, and tiered royalties on net sales for targets identified through the collaboration.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hitgen-amp-uppthera-collaborate-for-drug-delivery-research-nbsp\"><span class=\"ez-toc-section\" id=\"HitGen_UPPTHERA_Collaborate_for_Drug_Delivery_Research\"><\/span><strong>HitGen &amp; UPPTHERA Collaborate for Drug Delivery Research&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase.&nbsp;<\/p>\n\n\n\n<p>HitGen plans to apply its platform technology based on the design, synthesis, and screening of DNA-encoded libraries (DEL) for the discovery of compounds to bind to specific targets. UPPTHERA will have exclusive rights to those compounds, as per the agreement, for further development.&nbsp;<\/p>\n\n\n\n<p>In return, HitGen will receive an upfront payment, success fee, license\/milestone fee from UPPTHERA, details of which remain undisclosed.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-junshi-amp-astrazeneca-to-commercialize-toripalimab-in-china\"><span class=\"ez-toc-section\" id=\"Junshi_AstraZeneca_To_Commercialize_Toripalimab_in_China\"><\/span><strong>Junshi &amp; AstraZeneca To Commercialize Toripalimab in China<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Biopharmaceutical company Junshi Biosciences has collaborated with AstraZeneca to form an exclusive promotion deal for <strong>toripalimab <\/strong>in China for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/urothelial-carcinoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">Urothelial Carcinoma<\/a> indications. The collaboration will grant AZ the opportunity to commercialize the therapy in the geography for all approved indications and to be approved in non-core areas.<\/p>\n\n\n\n<p>The collaboration will help introduce innovative drugs into the Chinese pharmaceutical market. Further, Junshi Biosciences and AstraZeneca plan to explore other emerging markets and actively expand the length and breadth of their future deals and collaborations.<\/p>\n\n\n\n<p>Toripalimab is the first domestic anti-PD-1 monoclonal antibody that received approval for marketing in China. So far, Toripalimab has been granted 1 Breakthrough, 1 Fast Track, and 3 Orphan Drug Designations by the FDA to treat mucosal melanoma, nasopharyngeal carcinoma, and <a href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma-market-size-and-forecast\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">soft tissue sarcoma<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-artiva-raises-usd-120-m-to-advancing-allogeneic-nk-cell-therapy-pipeline\"><span class=\"ez-toc-section\" id=\"Artiva_Raises_USD_120_M_to_Advancing_Allogeneic_NK_Cell_Therapy_Pipeline\"><\/span><strong>Artiva Raises USD 120 M to Advancing Allogeneic NK Cell Therapy Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Artiva Biotherapeutics, an oncology-focus pharmaceutical company, announced the closing of its Series B financing round, raising a total sum of USD 120 million. The proceeds are collected to advance its allogeneic NK cell therapy development programs as well as augment ongoing research and development activities.&nbsp;<\/p>\n\n\n\n<p>As per the company, its manufacturing platform supports large-scale production and cryopreservation of off-the-shelf, allogeneic NK cell therapies and proprietary CAR-NK and NK-specific gene-editing technologies. The cell therapies use the innate anti-tumor biology and safety features of NK cells and target anti-cancer activity through CARs or ADCC enhancement through therapeutic antibody or innate-cell engager combination therapy. Its lead candidate, AB-101, an ADCC enhancer NK-cell therapy, is currently in a Phase I\/II study combined with rituximab for the treatment of relapsed or refractory <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-lymphomas-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">B-cell lymphomas<\/a>.\u00a0<\/p>\n\n\n\n<p>The financing was led by new investor Venrock Healthcare Capital Partners along with Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital, and others also participating in the financing. Existing investors, such as 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell and GC, also participated.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Evotec, Chinook Therapeutics to Advance Chronic Kidney Diseases Therapy Market Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine therapies for patients with chronic kidney diseases (CKD). The duo plans to jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines. The deal will help leverage Evotec&#8217;s proprietary PanOmics [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11839,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,2815,16902,1080,11601,16901,16888],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-11838","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-chronic-kidney-disease-ckd","tag-evotec","tag-nk-cell-therapies","tag-soft-tissue-sarcoma","tag-toripalimab","tag-urothelial-cancer","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evotec, Chinook&#039;s CKD Therapy; Junshi, AZ with Toripalimab in China<\/title>\n<meta name=\"description\" content=\"Evotec, Chinook Teams Up for CKD Therapy; Artiva $120 M Coup of NK Cell Therapy; Junshi &amp; AZ with Toripalimab in China; HitGen &amp; UPPTHERA...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evotec, Chinook&#039;s CKD Therapy; Junshi, AZ with Toripalimab in China\" \/>\n<meta property=\"og:description\" content=\"Evotec, Chinook Teams Up for CKD Therapy; Artiva $120 M Coup of NK Cell Therapy; Junshi &amp; AZ with Toripalimab in China; HitGen &amp; UPPTHERA...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-02T10:03:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T12:11:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/02152928\/Evotec-Chinooks-CKD-Therapy-Junshi-AZ-with-Toripalimab-in-China.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evotec, Chinook's CKD Therapy; Junshi, AZ with Toripalimab in China","description":"Evotec, Chinook Teams Up for CKD Therapy; Artiva $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China; HitGen & UPPTHERA...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen","og_locale":"en_US","og_type":"article","og_title":"Evotec, Chinook's CKD Therapy; Junshi, AZ with Toripalimab in China","og_description":"Evotec, Chinook Teams Up for CKD Therapy; Artiva $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China; HitGen & UPPTHERA...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-03-02T10:03:52+00:00","article_modified_time":"2025-02-12T12:11:18+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/02152928\/Evotec-Chinooks-CKD-Therapy-Junshi-AZ-with-Toripalimab-in-China.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen","name":"Evotec, Chinook's CKD Therapy; Junshi, AZ with Toripalimab in China","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/02152928\/Evotec-Chinooks-CKD-Therapy-Junshi-AZ-with-Toripalimab-in-China.jpg","datePublished":"2021-03-02T10:03:52+00:00","dateModified":"2025-02-12T12:11:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Evotec, Chinook Teams Up for CKD Therapy; Artiva $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China; HitGen & UPPTHERA...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-az-evotec-chinook-junshi-hitgen#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/02152928\/Evotec-Chinooks-CKD-Therapy-Junshi-AZ-with-Toripalimab-in-China.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/02152928\/Evotec-Chinooks-CKD-Therapy-Junshi-AZ-with-Toripalimab-in-China.jpg","width":772,"height":482,"caption":"Evotec, Chinook's CKD Therapy; Junshi, AZ with Toripalimab in China"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/02152928\/Evotec-Chinooks-CKD-Therapy-Junshi-AZ-with-Toripalimab-in-China-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic kidney disease (CKD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Evotec<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NK Cell Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Soft tissue Sarcoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Toripalimab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Urothelial Cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Chronic kidney disease (CKD)<\/span>","<span class=\"advgb-post-tax-term\">Evotec<\/span>","<span class=\"advgb-post-tax-term\">NK Cell Therapies<\/span>","<span class=\"advgb-post-tax-term\">Soft tissue Sarcoma<\/span>","<span class=\"advgb-post-tax-term\">Toripalimab<\/span>","<span class=\"advgb-post-tax-term\">Urothelial Cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Mar 2, 2021","modified":"Updated on Feb 12, 2025"},"absolute_dates_time":{"created":"Posted on Mar 2, 2021 3:33 pm","modified":"Updated on Feb 12, 2025 5:41 pm"},"featured_img_caption":"Evotec, Chinook's CKD Therapy;  Junshi, AZ with Toripalimab in China","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11838"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11838\/revisions"}],"predecessor-version":[{"id":31051,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11838\/revisions\/31051"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11839"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11838"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11838"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}